NSE: SANOFI | BSE: 500674

Mid-range Performer

Download real time

5056.50 17.00 (0.34%)

Near 52W Low of ₹4902.00

5,020 NSE+BSE Volume

NSE 16 Sep, 2025 11:31 AM (IST)

11,645.4

Market Cap

High in industry

0.4

Beta 1Year

Very Low volatility

Sanofi India Ltd. share price target and research reports

Name: Latest research reports of Sanofi India Ltd. authored by ICICI Securities Limited and published by - Trendlyne research reports.
Item: Sanofi India Ltd.
Rating: 5
Author: ICICI Securities Limited

Latest analyst research reports with target prices and PDF download for SANOFI, BSE:500674 Sanofi India Ltd.

Sanofi India Ltd.

27 Oct 2021

5056.50

0.34%

Sanofi India

Buy: Sanofi India Ltd.

Target

ICICI Securities Limited

Abbott India is one of the fastest growing listed MNC pharma companies. It has outperformed the industry on a consistent basis in women's health, GI, metabolic, pain, CNS among others. We continue to believe in Abbott's...

Sanofi India Ltd. has lost -29.34% in the last 1 Year

Sanofi India Ltd.

28 Jul 2021

5056.50

0.34%

Sanofi India

Buy: Sanofi India Ltd.

Target

ICICI Securities Limited

Sanofi India Ltd. is trading below all available SMAs

Sanofi India Ltd.

24 Feb 2021

5056.50

0.34%

Sanofi India

Buy: Sanofi India Ltd.

ICICI Securities Limited

Sanofi India Ltd. is trading below all available SMAs

Sanofi India Ltd.

28 Oct 2020

5056.50

0.34%

Sanofi India

Buy: Sanofi India Ltd.

Target

ICICI Securities Limited

Despite Covid-19, the company posted a decent 9MCY20 operational performance with EBITDA growing 12.1% YoY to | 546 crore mainly on the back of reduced other expenses (down 21% YoY) likely stemming from cost rationalisation, reduced marketing & promotional spends. Going ahead, we expect marketing spends to be lower than their historical trends on the back of higher adoption of digital marketing tools amid Covid-19. Sanofi remains one of the fastest growing companies in India in anti-diabetic therapy. It launched Toujeo within just three years of its launch in the US, which...

Sanofi India Ltd. is trading below all available SMAs

Sanofi India Ltd.

27 Oct 2020

5056.50

0.34%

Sanofi India

Buy: Sanofi India Ltd.

Sharekhan

Higher Share of Chronic, which provides a stable stream of revenues coupled with sustained traction from the top brands and margin expansion, due to favorable mix, to lead to double digit earnings growth over CY2019-CY2022E. Better growth prospects, low exposure to regulated markets, strong balance sheet, healthy cashflows, would continue to support premium valuations. Sanofi India (Sanofi), reported mixed performance for the quarter. Though the numbers are not comparable with the previous quarters as the company had hived off its Ankleshwar facility. The revenues for the quarter declined 11.9% y-o-y to Rs 687 crore...

Sanofi India Ltd. has lost -29.34% in the last 1 Year

Sanofi India Ltd.

29 Jul 2020

5056.50

0.34%

Sanofi India

Buy: Sanofi India Ltd.

ICICI Securities Limited

Despite Covid-19, the company posted a decent H1CY20 operational performance with EBITDA growing 13.6% YoY to | 354 crore mainly on the back of reduced other expenses (down 349 bps YoY) likely stemming from cost rationalisation, reduced marketing & promotional spends. Going ahead, we expect marketing spends to be lower than their historical trends on the back of higher adoption of digital marketing tools amid Covid-19. Sanofi remains one of the fastest growing companies in India in anti-diabetic therapy. It launched Toujeo within just three years of its launch in the US,...

Sanofi India Ltd. is trading below all available SMAs

Sanofi India Ltd.

20 Apr 2020

5056.50

0.34%

Sanofi India

Buy: Sanofi India Ltd.

Recommendation Target

ICICI Securities Limited

On the business front, despite the nationwide lockdown, domestic growth is expected to remain more or less stable. Exports growth, barring for one or two months due to congestion in all major ports globally, is also expected to remain strong due to 1) currency benefit, 2) slowdown in competition due to delay in new approvals that will be beneficial for existing players and 3) expected demand continuum across the world despite Covid-19. Some windfall is also expected in some critical productsa case in point is Hydroxychloroquine, a malaria drug that is likely to be repurposed as a prophylaxis for Covid-19 treatment in some cases....

Sanofi India Ltd. is trading below all available SMAs

Sanofi India Ltd.

27 Feb 2020

5056.50

0.34%

Sanofi India

Hold: Sanofi India Ltd.

Recommendation Target

ICICI Securities Limited

Power brands continue to grow ahead of industry growth The domestic pharma market (~| 1.4 trillion AIOCD MAT December 2019) is growing at 9-10% YoY. Branded generics dominate the pharmaceuticals market, constituting nearly 80% of market share in revenue terms. Sanofi's top five brands (Lantus, Combiflam, Allegra, Amaryl and Clexane) together posted revenue CAGR of ~14% (CY15-19), leading their combined contribution to Sanofi's India sales to grow from 44% in December 2015 to nearly 54% in December 2019. Note that four core brands (Lantus, Amaryl,...

Sanofi India Ltd. is trading below all available SMAs

Sanofi India Ltd.

16 Sep 2019, 12:00AM

5056.50

0.34%

Sanofi India

Buy: Sanofi India Ltd.

Target

ICICI Securities Limited

Although the deal prima facie looks unfavourable at 0.56x of EV/sales (| 262 crore realisation for a revenue of | 470 crore (17% of overall revenues), we expect a positive rub-off on the margins front, going ahead. As per the management's own assertion, the deal will lead to extended focus on its core branded formulations business that typically fetches better margins vis-vis third party exports. Despite this deal, the overall thesis for Sanofi remains unaltered as one of the fastest growing companies in India in antidiabetic therapy. It has launched Toujeo within just three years of its launch in the US, which suggests that it is prepared to launch core innovative products in India, banking on growth prospects in the anti-diabetic category....

Sanofi India Ltd. is trading below all available SMAs

Sanofi India Ltd.

30 Jul 2019

5056.50

0.34%

Earnings dip on lower Respiratory sales and higher opex

Buy: Sanofi India Ltd.

Motilal Oswal

Moderate revenue growth and inferior product mix lead PAT decline: Sales grew 9.4% YoY to INR7.5b (our est. INR7.7b) in 2QCY19. Gross margin (GM) shrank 600bp YoY to 54% due to change in the product mix and high inventory. Compared to GM, EBITDA margin contracted at a lower rate of 300bp YoY to 21.1% (our est. 21.7%) due to controlled other operating expense (down 310bp YoY as % of sales). Lower margins led EBITDA to...

Sanofi India Ltd. has lost -29.34% in the last 1 Year

Is Sanofi India Ltd. worth buying?

295 Votes:

Buy 79.66%

Sell 11.19%

Hold 9.15%